Voyager Therapeutics (NASDAQ:VYGR) Releases Earnings Results, Misses Expectations By $0.24 EPS

Voyager Therapeutics (NASDAQ:VYGR - Get Free Report) released its earnings results on Tuesday. The company reported ($0.59) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.24), Zacks reports. Voyager Therapeutics had a return on equity of 8.33% and a net margin of 15.80%.

Voyager Therapeutics Stock Down 4.8 %

Shares of NASDAQ:VYGR traded down $0.20 during trading on Tuesday, hitting $3.97. 549,596 shares of the company were exchanged, compared to its average volume of 493,491. The company has a market capitalization of $216.87 million, a P/E ratio of 5.59 and a beta of 0.99. Voyager Therapeutics has a 1-year low of $3.56 and a 1-year high of $10.66. The business's 50 day moving average is $4.98 and its 200-day moving average is $5.89.

Analyst Ratings Changes

A number of equities research analysts have issued reports on VYGR shares. Citigroup initiated coverage on shares of Voyager Therapeutics in a research note on Monday, December 2nd. They set a "buy" rating and a $12.00 price objective on the stock. Canaccord Genuity Group reiterated a "buy" rating and set a $14.00 price target on shares of Voyager Therapeutics in a research report on Thursday, November 14th. StockNews.com downgraded shares of Voyager Therapeutics from a "buy" rating to a "hold" rating in a research report on Friday, December 13th. Cantor Fitzgerald started coverage on Voyager Therapeutics in a research note on Friday, January 10th. They set an "overweight" rating and a $5.73 target price for the company. Finally, Wedbush reiterated an "outperform" rating and issued a $9.00 price target (down previously from $11.00) on shares of Voyager Therapeutics in a research note on Tuesday, February 11th. One research analyst has rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Voyager Therapeutics has an average rating of "Buy" and an average price target of $15.72.

Remove Ads

Insiders Place Their Bets

In other news, COO Robin Swartz sold 6,500 shares of the business's stock in a transaction dated Monday, December 23rd. The stock was sold at an average price of $5.65, for a total transaction of $36,725.00. Following the sale, the chief operating officer now directly owns 112,328 shares in the company, valued at approximately $634,653.20. The trade was a 5.47 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders sold a total of 10,778 shares of company stock valued at $58,548 in the last 90 days. Corporate insiders own 4.53% of the company's stock.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.